Maze Therapeutics reported clinically meaningful Phase 2 top-line results for MZE829, an oral APOL1 inhibitor being tested in patients with broad APOL1-mediated kidney disease. The company said the drug delivered an average 35.6% reduction in urine protein levels measured by uACR at week 12 across 12 efficacy-evaluable participants. Maze plans to continue enrollment in its Horizon Phase 2 program and aims to meet with regulators to advance toward a pivotal trial. Results also showed stronger proteinuria reductions in FSGS subgroups and among patients without diabetes, which could shape how the company talks about efficacy breadth. Investors reacted negatively to the stock despite the positive readout, reflecting how high expectations for disease-modifying renal therapies can intensify volatility around early-stage endpoints. For the field, AMKD remains a sought-after precision indication with limited approved options, making differentiation around effect size and patient stratification critical for any competitor looking to take market share from Vertex’s approach.